<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
   <channel>
      <title>Regulatory Affairs/Drug Approvals News</title>
      <link>http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/</link>
      <description>Regulatory Affairs/Drug Approvals News</description>
      <language>en-en</language>
      <webMaster>padayatra@bk.ru</webMaster>
      <copyright>http://poznaisebya.com/newseng</copyright>
      <pubDate>Sat, 22 Nov 2008 15:45:14 GMT.</pubDate>
      <lastBuildDate>Sat, 21 Jun 2008 22:20:07 GMT</lastBuildDate>
      <image>
         <title>Regulatory Affairs/Drug Approvals News</title>
         <url>http://poznaisebya.com/newseng/i/logo.png</url>
         <link>http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/</link>
      </image>

      <item>
         <title>GSK Update On FDA Review Of Promacta R Eltrombopag </title>
         <link>http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-21-22-20-07-522.html</link>
         <description>GlaxoSmithKline (NYSE: GSK) announced that the United States Food and Drug Administration has extended the priority review period for PROMACTA(R) (eltrombopag) for the short-term treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura,  as they require more time to review the application.   
&lt;br&gt;&lt;p&gt;&lt;a href=http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-21-22-20-07-522.html&gt;Full text&lt;/a&gt;&lt;/p&gt;</description>
         <pubDate>Sat, 21 Jun 2008 22:20:07 GMT</pubDate>
      </item>

      <item>
         <title>FDA Approves GlaxoSmithKline&#039;s AVODART R In Combination With Tamsulosin For The Treatment Of Symptomatic Enlarged Prostate</title>
         <link>http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-21-22-20-04-909.html</link>
         <description>GlaxoSmithKline (NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has approved AVODART (dutasteride) in combination with tamsulosin for the treatment of symptomatic enlarged prostate,  a disease that affects half of all men over 50 years old.   
&lt;br&gt;&lt;p&gt;&lt;a href=http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-21-22-20-04-909.html&gt;Full text&lt;/a&gt;&lt;/p&gt;</description>
         <pubDate>Sat, 21 Jun 2008 22:20:04 GMT</pubDate>
      </item>

      <item>
         <title>FDA Warns Individuals And Firms To Stop Selling Fake Cancer &#039;Cures&#039;</title>
         <link>http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-20-18-20-05-656.html</link>
         <description>Warning Letters have been sent to 23 U.S. companies and two foreign individuals marketing a wide range of products fraudulently claiming to prevent and cure cancer,  according to the U.   
&lt;br&gt;&lt;p&gt;&lt;a href=http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-20-18-20-05-656.html&gt;Full text&lt;/a&gt;&lt;/p&gt;</description>
         <pubDate>Fri, 20 Jun 2008 18:20:05 GMT</pubDate>
      </item>

      <item>
         <title>FDA Advisory Committee Unanimously Recommends Approval Of Ustekinumab For Treatment Of Moderate To Severe Plaque Psoriasis</title>
         <link>http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-20-18-20-04-642.html</link>
         <description>Centocor,  Inc. announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the U.   
&lt;br&gt;&lt;p&gt;&lt;a href=http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-20-18-20-04-642.html&gt;Full text&lt;/a&gt;&lt;/p&gt;</description>
         <pubDate>Fri, 20 Jun 2008 18:20:04 GMT</pubDate>
      </item>

      <item>
         <title>FDA Approves Cymbalta reg; For The Management Of Fibromyalgia</title>
         <link>http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-20-18-20-03-191.html</link>
         <description>The U.S. Food and Drug Administration (FDA) has approved Cymbalta (duloxetine HCl) for the management of fibromyalgia,  a chronic widespread pain disorder,  Eli Lilly and Company (NYSE: LLY) announced.   
&lt;br&gt;&lt;p&gt;&lt;a href=http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-20-18-20-03-191.html&gt;Full text&lt;/a&gt;&lt;/p&gt;</description>
         <pubDate>Fri, 20 Jun 2008 18:20:03 GMT</pubDate>
      </item>

      <item>
         <title>Deaths May Have Been Caused By Abortion Drug&#039;s Off-Label Use</title>
         <link>http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-19-15-00-11-776.html</link>
         <description>Preliminary U-M studies indicate that oral use of RU-486&#039;s companion drug misoprostol is safe,  but vaginal use may undermine body&#039;s immune responsesThe off-label use of a drug given with RU-486 to terminate a pregnancy may be responsible for a handful of rare,  fatal infections seen in women taking the drugs since 2000,  a study by University of Michigan scientists suggests.   
&lt;br&gt;&lt;p&gt;&lt;a href=http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-19-15-00-11-776.html&gt;Full text&lt;/a&gt;&lt;/p&gt;</description>
         <pubDate>Thu, 19 Jun 2008 15:00:11 GMT</pubDate>
      </item>

      <item>
         <title>Nationwide Data Indicate A Very High Degree Of Accuracy For OraQuick ADVANCE Rapid HIV-1 2 Antibody Test With Oral Fluid</title>
         <link>http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-19-15-00-10-652.html</link>
         <description>OraSure Technologies,  Inc. (NASDAQ:OSUR) announced that aggregate nationwide performance data for 2007 and the first five months of 2008 indicate that its widely used rapid HIV-1/2 antibody screening test,  OraQuick ADVANCE,   has a very high degree of accuracy with oral fluid - at rates that are within the U.   
&lt;br&gt;&lt;p&gt;&lt;a href=http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-19-15-00-10-652.html&gt;Full text&lt;/a&gt;&lt;/p&gt;</description>
         <pubDate>Thu, 19 Jun 2008 15:00:10 GMT</pubDate>
      </item>

      <item>
         <title>Cook Medical Enters Coronary Stent Market In Europe With New CoCr Stent</title>
         <link>http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-19-15-00-09-377.html</link>
         <description>Global Therapeutics,  the cardiology unit of Cook Medical,  has received CE Mark approval for a new cobalt chromium bare metal coronary stent that company executives believe will fill a demand for non-drug eluting coronary stents among interventional cardiologists,  the company announced today.   
&lt;br&gt;&lt;p&gt;&lt;a href=http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-19-15-00-09-377.html&gt;Full text&lt;/a&gt;&lt;/p&gt;</description>
         <pubDate>Thu, 19 Jun 2008 15:00:09 GMT</pubDate>
      </item>

      <item>
         <title>Synapse Biomedical Receives FDA Approval Of NeuRx Diaphragm Pacing System DPS TM For Spinal Cord Injury Breathing Applications</title>
         <link>http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-19-15-00-08-866.html</link>
         <description>Synapse Biomedical Inc. (http://www.synapsebiomedical.com) announced it has received approval from the U.   
&lt;br&gt;&lt;p&gt;&lt;a href=http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-19-15-00-08-866.html&gt;Full text&lt;/a&gt;&lt;/p&gt;</description>
         <pubDate>Thu, 19 Jun 2008 15:00:08 GMT</pubDate>
      </item>

      <item>
         <title>European Medicines Agency Recommends Measures To Manage Contamination Ofheparin-Containing Medicines</title>
         <link>http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-17-08-00-06-900.html</link>
         <description>The European Medicines Agency has reviewed the risks associated with the use of heparin medicinal products contaminated with oversulphated chondroitin sulphate (OSCS).   
&lt;br&gt;&lt;p&gt;&lt;a href=http://poznaisebya.com/newseng/regulatory-affairs-drug-approvals-news/news_2008-06-17-08-00-06-900.html&gt;Full text&lt;/a&gt;&lt;/p&gt;</description>
         <pubDate>Tue, 17 Jun 2008 08:00:06 GMT</pubDate>
      </item>

   </channel>
</rss>
